RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
November 05 2020 - 6:00AM
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”),
a specialty biopharmaceutical company, today announced that it will
report its third-quarter 2020 financial results and business
highlights on Thursday, November 12, 2020.
The Company will host a conference call and
webcast on Thursday,
November 12,
2020, at 8:30 a.m.
EST, during
which it will present key highlights for the third quarter of 2020,
including:
-
Financial performance for the quarter ended September 30,
2020;
-
Commercial activities status;
-
The progress of the late-stage development program with opaganib
for COVID-19 and preparation for potential emergency use
applications;
-
Pipeline progress, including the granting of Orphan Drug
Designation and the Phase 3 study with RHB-204 for first-line
pulmonary nontuberculous mycobacteria (NTM) infections.
The webcast and slides will be broadcasted live
on the Company's website:
http://ir.redhillbio.com/events and available for
replay for 30 days.
To participate in the conference call, please
dial one of the following numbers 15 minutes prior to the start of
the call: United States:
+1-877-870-9135;
International:
+1-646-741-3167
and Israel:
+972-3-530-8845;
the access code for the call is:
4549918.
About RedHill BiopharmaRedHill
Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical
company primarily focused on gastrointestinal and infectious
diseases. RedHill promotes the gastrointestinal drugs,
Movantik® for opioid-induced
constipation in adults1, Talicia® for the
treatment of Helicobacter pylori (H. pylori) infection in adults2,
and Aemcolo® for the treatment of travelers’
diarrhea in adults3. RedHill’s key clinical late-stage development
programs include: (i) RHB-204, with a planned
Phase 3 study for pulmonary nontuberculous mycobacteria (NTM)
infections; (ii) opaganib
(Yeliva®), a
first-in-class SK2 selective
inhibitor targeting multiple indications with a Phase 2/3 program
for COVID-19 and Phase 2 studies for prostate cancer and
cholangiocarcinoma ongoing; (iii) RHB-104, with
positive results from a first Phase 3 study for Crohn's disease;
(iv) RHB-102 (Bekinda®), with
positive results from a Phase 3 study for acute gastroenteritis and
gastritis and positive results from a Phase 2 study for IBS-D; (v)
RHB-107, a Phase 2-stage first-in-class, serine
protease inhibitor, targeting cancer and inflammatory
gastrointestinal diseases and is also being evaluated for COVID-19
and (vi) RHB-106, an encapsulated
bowel preparation. More information about the Company is available
at www.redhillbio.com.
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are based
on certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control and cannot be predicted or quantified, and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the initiation, timing, progress and results of
the Company’s research, manufacturing, pre-clinical studies,
clinical trials, and other therapeutic candidate development
efforts, and the timing of the commercial launch of its commercial
products and ones it may acquire or develop in the future; (ii) the
Company’s ability to advance its therapeutic candidates into
clinical trials or to successfully complete its pre-clinical
studies or clinical trials or the development of a commercial
companion diagnostic for the detection of MAP; (iii) the extent and
number and type of additional studies that the Company may be
required to conduct and the Company’s receipt of regulatory
approvals for its therapeutic candidates, and the timing of other
regulatory filings, approvals and feedback; (iv) the manufacturing,
clinical development, commercialization, and market acceptance of
the Company’s therapeutic candidates and Talicia®; (v) the
Company’s ability to successfully commercialize and promote
Talicia®, and Aemcolo® and Movantik®; (vi) the Company’s
ability to establish and maintain corporate collaborations; (vii)
the Company's ability to acquire products approved for marketing in
the U.S. that achieve commercial success and build its own
marketing and commercialization capabilities; (viii) the
interpretation of the properties and characteristics of the
Company’s therapeutic candidates and the results obtained with its
therapeutic candidates in research, pre-clinical studies or
clinical trials; (ix) the implementation of the Company’s business
model, strategic plans for its business and therapeutic candidates;
(x) the scope of protection the Company is able to establish and
maintain for intellectual property rights covering its therapeutic
candidates and its ability to operate its business without
infringing the intellectual property rights of others; (xi) parties
from whom the Company licenses its intellectual property defaulting
in their obligations to the Company; (xii) estimates of the
Company’s expenses, future revenues, capital requirements and needs
for additional financing; (xiii) the effect of patients suffering
adverse experiences using investigative drugs under the Company's
Expanded Access Program; (xiv) competition from other companies and
technologies within the Company’s industry; and (xv) the hiring and
employment commencement date of executive managers. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission
(SEC), including the Company's Annual Report on Form 20-F filed
with the SEC on March 4, 2020. All forward-looking statements
included in this press release are made only as of the date of this
press release. The Company assumes no obligation to update any
written or oral forward-looking statement, whether as a result of
new information, future events or otherwise unless required by
law.
Company contact:Adi FrishChief Corporate &
Business Development OfficerRedHill
Biopharma+972-54-6543-112adi@redhillbio.com |
Media contact (U.S.):Bryan GibbsVice PresidentFinn
Partners+1 212 529 2236bryan.gibbs@finnpartners.com |
_________________________________________________
1 Full prescribing information for Movantik® (naloxegol) is
available at: www.Movantik.com.2 Full prescribing information
for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is
available at: www.Talicia.com.3 Full prescribing information for
Aemcolo® (rifamycin) is available at: www.Aemcolo.com.
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Apr 2024 to May 2024
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From May 2023 to May 2024